

LentiGlobin for SCD Update

March 10, 2021

LETS
RECODE
THE STORY

Forward-looking Statements

These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward-looking statements. For example, all statements we make regarding the progress and results of our ongoing investigation into the two safety events recently reported in the HGB-206 clinical study, as well as potential regulatory interactions for the HGB-206 and HGB-210 clinical studies, as well as for marketing of ZYNTEGLO®, are forward looking. All forwardlooking statements are based on expectations, estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These statements are also subject to a number of material risks and uncertainties that are described in our most recent annual report on Form 10-K, as well as our subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.



AML Case: Questions we have sought to address

Are classical AML driver mutations present?

- Mutations in the RUNX1 and PTPN11 genes
- Gross chromosomal abnormalities including:
 - Monosomy 7
 - Partial loss of 11p



Is the site of vector integration unremarkable?

- Insertion in VAMP4 (Vesicle-associated membrane protein 4)
- No known role in cellular proliferation or genome stability
- Totality of public/published data consistent with no role in cancer
- VAMP4 insertions seen in the majority of HGB-206 patients without sequalae



Is the vector inert in the AML cells?

- Vector-encoded β -globin promoter / enhancer is minimally active in tumor cells (based on T87Q expression)
- No gene misregulation across a ~1MB region surrounding vector integration site



Moving Forward for Patients with SCD

Today


- AML case: vector unlikely to have played a role
- MDS case: diagnosis under evaluation; no blasts, no dysplasia, clinically stable
- Engaged with regulators to resume HGB-206 and HGB-210
- Engaged with EMA to renew ZYTENGLO cMAA

Looking Ahead

- Further detail on MDS case
- Clarity on resumption of clinical studies and EU marketing
- Planned company split on track



Simple Vision; Profound Mission



We care in a way that's intense and truly sets us apart.

CARE



Gene therapy is about saving lives one person at a time.
And we are, each of us, personally all in.



We're exploring new frontiers for the sake of patients.